A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

Study acronym: ACCLAIM-CTA
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 7 months later Apr 2029 → Dec 2029
See other at-risk trials from Eli Lilly

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 3 of 58 sites
  2. Eligibility criteria expanded, about 11 words
    • Study sites revised (58)
  3. Site details revised at 7 of 58 sitesv8
  4. Site details revised at 14 of 58 sitesv7
  5. Study sites revised (58)v6
  6. Primary and study completion pushed from Apr 2029 to Dec 2029
    • Site contacts updated at 5 of 58 sites
    v5
  7. Study sites: 59 to 58
    • Start date: Jun 2, 2026 to Jun 1, 2026
    v4
  8. Study Status, Referencesv3
  9. Recruitment opened
    • Study sites: 58 to 59
    • Start date changed from estimate of May 2026 to Jun 2, 2026
    v2
  10. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
366 trials monitored
See 16 trials at risk
Heart Disease
8,870 trials monitored
See 440 trials at risk
Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart disease. The main purpose of the study is to investigate how lepodisiran, compared to a placebo, affects the amount and type of plaque in the heart's vessels using an imaging technology known as Coronary Computed Tomography Angiography (CCTA) in adults who have high levels of Lp(a). Participation will last about 120 weeks.
Trial Details
NCT Number NCT07613294
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
Related terms Atherosclerosis, Cardiovascular Diseases
Enrollment 252 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov